BiotechTube

Abatacept

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Juvenile Idiopathic Arthritis

Conditions

Juvenile Idiopathic Arthritis

Trial Timeline

Aug 9, 2013 → Jul 30, 2018

NCT ID
NCT01835470

About Abatacept

Abatacept is a phase 3 stage product being developed by Ono Pharmaceutical for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01835470. Target conditions include Juvenile Idiopathic Arthritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01835470Phase 3Completed

Competing Products

20 competing products in Juvenile Idiopathic Arthritis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
69
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
AdalimumabEisaiPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
BaricitinibEli LillyPhase 3
77
Baricitinib + TocilizumabEli LillyPhase 3
77
adalimumab + MethotrexateAbbViePre-clinical
23
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
77
Adalimumab + RisankizumabAbbViePhase 3
77
AdalimumabAbbViePhase 3
77
naproxen + esomeprazoleAstraZenecaPhase 1
33
Alendronate (Fosamax)MerckPre-clinical
23
canakinumabNovartisPhase 3
77
SecukinumabNovartisPhase 1
33
ACZ885 150 mg (Canakinumab)NovartisPhase 3
77

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77